Iranian Knowledge-Based Company Ready to Meet Middle-East, North Africa’s Needs to HPV Vaccine
“Iran is the third country which produces the vaccine and can have a significant share in the international market of the vaccine. It is expected that with the mass production of this vaccine in the coming years, we will see the annual income of nearly $50 million,” said Amin Qobadi.
Noting that the vaccine was mass-produced to enter the market after approval of the clinical trial and three years of research and development and production in the laboratory and semi-industrial dimensions, he added, “Papillogard is a recombinant vaccine to provide complete protection against types 16 and 18 of the human papilloma virus.”
“This virus causes 70% of HPV-related cancers, and vaccination is the best way to prevent it,” Qobadi said, adding, “Our company enjoys the capacity to produce 15 million doses of the vaccine per year, and we can completely meet the needs of the Middle East and North African region.”
Human papillomavirus (HPV) is the name of a very common group of viruses. They do not cause any problems in most people, but some types can cause genital warts or cancer.
HPV affects the skin. There are more than 100 different types.
HPV does not usually cause any symptoms. Most people who have it do not realise and do not have any problem. But sometimes the virus can cause painless growths or lumps around your vagina, penis or anus. Many types of HPV affect the mouth, throat or genital area.
4155/v
